Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 13 957 / https://doi.org/10.3332/ecancer.2019.957

Clinical Study

Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis

Objective: Extended-field radiotherapy (EFRT) with concurrent chemotherapy represents standard treatment in cervical cancer patients with para-aortic lymph nodal (PALN) metastasis. While EFRT with Intensity Modulated RT (IMRT) has been demonstrated to reduce toxicities, the dose thresholds for minimizing acute toxicity is not clear. The present study was undertaken to report the early toxicity with extended-field intensity-modulated radiotherapy (EF-IMRT) for carcinoma of the cervix in our cohort of patients and determine dose-volume parameters that predict ≥grade II haematological toxicity and diarrhoea.

Methodology: This was a retrospective study of consecutive cervical cancer patients with PALN metastasis treated with EF-IMRT. Patients received rotational IMRT /- neoadjuvant chemotherapy (NACT) and/or concurrent chemotherapy (45–50 Gy/25#/5 weeks) followed by high-dose rate brachytherapy. Acute haematological and gastrointestinal toxicity (diarrhoea and vomiting) was correlated with doses received by bowel and marrow. Receiver operator characteristics curves were used for deriving thresholds that predict for increased toxicity and tested on univariate and multivariate analysis. Finally, disease free and overall survival (DFS and OS) was calculated.

Results: A total of 43 patients were included. One-fourth of the patients (11/43) received NACT and 88% received concurrent chemotherapy. Within the upfront EF-IMRT cohort, 22.6% and 9.7% patients developed grade ≥III haematological (HT) and gastrointestinal (GI) toxicity respectively, with an increase in HT (≥ grade III HT =67%) in patients receiving NACT (p = 0.007). In the entire cohort bone marrow Volume receiving 10 Gy (V10>) 90% correlated with an increase in ≥ grade III HT (p = 0.05). No dose volume thresholds could be validated for GI toxicity. The OS and DFS at 2 years was 56% and 54%, respectively.

Conclusion: EF-IMRT is a feasible option for cervical cancer patients with PALN involvement and is associated with acceptable grade III toxicity. Future studies need to focus on minimizing HT toxicity.

Keywords: cervical cancer, PALN, EFRT, IMRT, toxicity

Loading Article Metrics ... Please wait

Related articles

Research: Health-related quality of life before and during chemotherapy in patients with early-stage breast cancer

Abstract | Full Article | PDF Published: 27 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1007

Case Report: Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature

Abstract | Full Article | PDF Published: 23 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1006

Short Communication: Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution

Abstract | Full Article | PDF Published: 23 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1005

Research: Socio-culturally mediated factors and lower level of education are the main influencers of functional cervical cancer literacy among women in Mayuge, Eastern Uganda

Abstract | Full Article | PDF Published: 21 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1004

Research: High depletion of breast cancer cells from the peripheral blood with the method of non-specific separation

Abstract | Full Article | PDF Published: 21 Jan 2020 / https://doi.org/10.3332/ecancer.2020.1003



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation